BREAKING: JP Morgan to Invest in the $1 Trillion Pill

I believe we’re now less than six months away from the first... [Energy and Capital Header] Practical Investment Analysis for the New Energy Economy BREAKING: JP Morgan to Invest in the $1 Trillion Pill Jeff Siegel | Mar 08, 2024 It’s not rocket science. Want to get to the good grass first? Just follow the money. And in this case, that “money” is JP Morgan. A few weeks ago, during a closed-door meeting, a managing partner at J.P. Morgan shared a small piece of intel that probably was never meant to leave the room. His name is Dr Gaurav Gupta, and he let it slip that the behemoth investment bank (with assets in excess of $2.5 trillion), is now in dialogue with a number of companies developing new EN-23 treatments for mental health conditions. If you’re unfamiliar, EN-23 is a valuable class of molecules that drastically improves brain function. It’s actually one of the biggest breakthroughs medical science has seen in 50 years, because not only can it treat mental health conditions such as depression, anxiety, PTSD and addiction, it also has the ability to help you … - Learn new complex mathematical equations - Learn foreign languages in a matter of months - Improve your sex life - Treat chronic pain - Lose weight It’s even been suggested that it could extend your lifespan by as much as 20 years! URGENT: Look at This Map of America... [TWA EV Payouts after map] There’s a silent invasion happening. Those black dots you see are electric vehicle charging stations — but they’re not like any chargers you’ve seen before. Because every one of those units could soon be putting money directly into your bank account... Twenty-four hours a day, seven days a week. [Click here to discover what may be the biggest income opportunity of your lifetime.]( Now it should be understood that EN-23 is not new. This class of molecules has actually been undergoing FDA clinical trials for more than a decade. But what’s interesting is that the very first EN-23 molecule to be approved by the FDA is expected to happen this year. August 11th, to be exact. So it’s no coincidence that J.P. Morgan is getting active in the space.  It’s also no coincidence that January was the second-highest fundraising month on record for the EN-23 sector. And once the numbers come in, it’s likely that Q1 2024 fundraising numbers will be the highest ever for the sector. I believe we’re now less than six months away from the first EN-23 medication being approved by the FDA. And once that happens, the flood gates are going to open, because the smart money will now have the evidence it needs to know that the FDA is willing to approve EN-23 medications. J.P. Morgan, Goldman Sachs, Morgan Stanley — they’ve all been preparing for this FDA approval for years, and they have a mountain of capital they’re going to pony up for a piece of this market. A market, by the way, that’s actually been valued at more than $1 trillion. 9 Billionaires Shifting Funds Here (Plus Warren Buffett) The smartest investors in the world are making a BIG move right now. David Tepper, Steve Cohen, Bill Gross, Paul Tudor Jones, Jeremy Grantham, George Soros, Carl Icahn, Jim Simons, and Larry Fink... They're jumping into oil and gas stocks with both feet. Meanwhile, 99% of investors can’t see what’s coming. According to Keith Kohl, our oil and gas analyst, three powerful economic triggers are converging on the oil markets right now... A "perfect storm" unlike anything we’ve seen in 50 years. The last time this happened, a small group of oil companies made 20x returns in a few years. Some gains were as high as 3,000%! That’s exactly the type of oil company Keith is recommending today.  He’s calling it "the No. 1 oil stock of the decade." [Get the name and ticker here before oil prices surge higher.]( That’s trillion — with a “T.” And if you don’t believe it, just [look at the numbers for yourself.]( Some have even called EN-23 the $1 Trillion Pill. Now the company that’s about to get its EN-23 medication approved by the FDA is not public. But there are three other EN-23 companies on the cusp of FDA approval, too. And not only are they public, they’re also trading at huge discounts right now. All three are flush with cash, are directly connected to the pharmaceutical industry, and have a diversified portfolio of drug development programs that are currently in FDA clinical trials. In other words, once the FDA approves the first EN-23 medication in August,these three companies]( will be next in line for FDA approval. And you want in before that happens. Because if you know anything about what happens to a biotech stock after FDA approval, you know how important it is to get in early. Consider Reata Pharmaceuticals (NASDAQ: RETA), for instance, which climbed 175% after the FDA approved its treatment for a rare disease called Friedreich's ataxia [lmt1] Or Vanda Pharmaceuticals (NASDAQ: VNDA), which shot up 643% following FDA approval of its schizophrenia drug  [lmt11] Or Aquinox Pharmaceuticals (NASDAQ: AQXP), which soared 950% after announcing favorable test results for a drug it developed to treat bladder cancer … [lmt111] But these gains are peanuts compared to what we expect after the FDA approves EN-23. And it’s going to happen soon. So please don’t underestimate the magnitude of this opportunity. And please don’t sit on the sidelines while the smart money is strategically investing in the EN-23 market right now. Mark my words: once the FDA approves the first EN-23 medication ever, every trend-chaser on Wall Street will be loading up the boat. And that’s when you’ll be able to cash out for what could easily be [your biggest win ever.]( To a new way of life and a new generation of wealth... [Jeff Siegel Signature] Jeff Siegel [[follow basic]Check us out on YouTube!]( [[follow basic]@JeffSiegel on Twitter]( Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor's [page](. [Fb]( [Li]( [Tw]( This email was sent to {EMAIL}. You can manage your subscription and get our privacy policy [here](. Energy and Capital, Copyright © 3 East Read Street, Baltimore, MD 21202. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info [here]( including our privacy policy and information on how to manage your subscription. If you are interested in our other publications, please call our customer service team at [1-877-303-4529](tel:/18773034529).